CHEMOTHERAPY IN HEAD AND NECK CANCER: Overview of Newer Agents

This publication has 12 references indexed in Scilit:

• Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
  Journal of Clinical Oncology, 1998
• Efficacy and safety of docetaxel in clinical trials.
  American Journal of Health-System Pharmacy, 1997
• Docetaxel in der Behandlung anderer solider Tumoren
  Medizinische Klinik, 1997
• Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer—Results from a phase I trial
  International Journal of Radiation Oncology*Biology*Physics, 1997
• A Phase II Study of Topotecan in Patients with Recurrent Head and Neck Cancer
  American Journal of Clinical Oncology, 1997
• Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck
  Investigational New Drugs, 1996
• Gemcitabine and radiosensitization in human tumor cells
  Investigational New Drugs, 1996
• Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
  Annals of Oncology, 1994
• In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells
  JNCI Journal of the National Cancer Institute, 1994
• Head and Neck Cancer
  New England Journal of Medicine, 1993